Frank J Penedo1, Rina S Fox2, Emily A Walsh3, Betina Yanez2, Gregory E Miller4, Laura B Oswald5, Ryne Estabrook6, Robert T Chatterton7, David C Mohr8, Mark J Begale9, Sarah C Flury10, Kent Perry10, Shilajit D Kundu10, Patricia I Moreno11. 1. Department of Psychology, University of Miami, United States; Department of Medicine, University of Miami Miller School of Medicine, United States. Electronic address: frank.penedo@miami.edu. 2. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, United States. 3. Department of Psychology, University of Miami, United States. 4. Institute for Policy Research and Department of Psychology, Northwestern University, United States. 5. Health Outcomes and Behavior Program, H. Lee Moffitt Cancer Center & Research Institute, United States. 6. Department of Psychology, University of Illinois at Chicago, United States. 7. Department of Obstetrics & Gynecology, Northwestern University Feinberg School of Medicine, United States. 8. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, United States. 9. Vibrent Health, United States. 10. Department of Urology, Northwestern University Feinberg School of Medicine, United States. 11. Department of Public Health Sciences, University of Miami Miller School of Medicine, United States.
Abstract
Cognitive behavioral stress management (CBSM) improves quality of life and mitigates stress biology in patients with early-stage cancer, including men with localized prostate cancer. However, treatments for advanced prostate cancer like androgen deprivation therapy (ADT) can lead to significant symptom burden that may be further exacerbated by stress-induced inflammation and cortisol dysregulation. The aim of this study was to examine the effects of CBSM (versus an active health promotion control) on circulating inflammatory markers and cortisol in men with advanced prostate cancer. METHODS: Men with stage III or IV prostate cancer (N = 192) who had undergone ADT within the last year were randomized to CBSM or health promotion. Both interventions were 10 weeks, group-based, and delivered online. Venous blood was drawn at baseline, 6 months, and 12 months to measure circulating levels of CRP, IL-6, IL-8, IL-10, and TNF-α. Saliva samples were collected at awakening, 30 min after awakening, evening, and night for two consecutive days at baseline, 6-months, and 12-months to measure diurnal cortisol slopes. RESULTS: Mixed modeling analyses demonstrated that changes in inflammatory markers and cortisol did not differ by intervention. Men in both CBSM and health promotion showed decreases in IL-10, IL-8, and TNF-α from baseline to 6 months (β = -3.85--5.04, p's = 0.004-<0.001). However, these markers generally demonstrated a rebound increase from 6 to 12 months (β = 1.91-4.06, p's = 0.06-<0.001). Men in health promotion also demonstrated a flatter diurnal cortisol slope versus men in CBSM at 6 months (β = -2.27, p = .023), but not at 12 months. There were no intervention effects on CRP, IL-6, or overall cortisol output. CONCLUSIONS: Contrary to hypotheses, CBSM did not lead to changes in the circulating inflammatory markers and cortisol relative to health promotion. CBSM may be associated with healthy diurnal cortisol rhythm because of its focus on cognitive behavioral approaches to stress management. More research is needed to understand the impact of CBSM and health promotion on biomarkers among men with advanced prostate cancer.
Cognitive behavioral stress management (CBSM) improves quality of life and mitigates stress biology in patients with early-stage cancer, including men with localized prostate cancer. However, treatments for advanced prostate cancer like androgen deprivation therapy (ADT) can lead to significant symptom burden that may be further exacerbated by stress-induced inflammation and cortisol dysregulation. The aim of this study was to examine the effects of CBSM (versus an active health promotion control) on circulating inflammatory markers and cortisol in men with advanced prostate cancer. METHODS: Men with stage III or IV prostate cancer (N = 192) who had undergone ADT within the last year were randomized to CBSM or health promotion. Both interventions were 10 weeks, group-based, and delivered online. Venous blood was drawn at baseline, 6 months, and 12 months to measure circulating levels of CRP, IL-6, IL-8, IL-10, and TNF-α. Saliva samples were collected at awakening, 30 min after awakening, evening, and night for two consecutive days at baseline, 6-months, and 12-months to measure diurnal cortisol slopes. RESULTS: Mixed modeling analyses demonstrated that changes in inflammatory markers and cortisol did not differ by intervention. Men in both CBSM and health promotion showed decreases in IL-10, IL-8, and TNF-α from baseline to 6 months (β = -3.85--5.04, p's = 0.004-<0.001). However, these markers generally demonstrated a rebound increase from 6 to 12 months (β = 1.91-4.06, p's = 0.06-<0.001). Men in health promotion also demonstrated a flatter diurnal cortisol slope versus men in CBSM at 6 months (β = -2.27, p = .023), but not at 12 months. There were no intervention effects on CRP, IL-6, or overall cortisol output. CONCLUSIONS: Contrary to hypotheses, CBSM did not lead to changes in the circulating inflammatory markers and cortisol relative to health promotion. CBSM may be associated with healthy diurnal cortisol rhythm because of its focus on cognitive behavioral approaches to stress management. More research is needed to understand the impact of CBSM and health promotion on biomarkers among men with advanced prostate cancer.
Authors: Stefan Holmstrom; Shevani Naidoo; James Turnbull; Emily Hawryluk; Jean Paty; Robert Morlock Journal: Patient Date: 2019-02 Impact factor: 3.883
Authors: Michael H Antoni; Sarah R Wimberly; Suzanne C Lechner; Aisha Kazi; Tammy Sifre; Kenya R Urcuyo; Kristin Phillips; Roselyn G Smith; Vida M Petronis; Sophie Guellati; Kurrie A Wells; Bonnie Blomberg; Charles S Carver Journal: Am J Psychiatry Date: 2006-10 Impact factor: 18.112
Authors: Michelle C Janelsins; Paul G Davis; Laurie Wideman; Jeffrey A Katula; Lisa K Sprod; Luke J Peppone; Oxana G Palesh; Charles E Heckler; Jacqueline P Williams; Gary R Morrow; Karen M Mustian Journal: Clin Breast Cancer Date: 2011-04-20 Impact factor: 3.225
Authors: Mary-Frances O'Connor; Julie E Bower; Hyong Jin Cho; J David Creswell; Stoyan Dimitrov; Mary E Hamby; Michael A Hoyt; Jennifer L Martin; Theodore F Robles; Erica K Sloan; Kamala S Thomas; Michael R Irwin Journal: Brain Behav Immun Date: 2009-04-21 Impact factor: 7.217
Authors: Suzanne K Chambers; Elizabeth Foley; Samantha Clutton; Robert McDowall; Stefano Occhipinti; Martin Berry; Martin R Stockler; Stephen J Lepore; Mark Frydenberg; Robert A Gardiner; Ian D Davis; David P Smith Journal: Qual Life Res Date: 2016-06-17 Impact factor: 4.147
Authors: Aeson Chang; Erica K Sloan; Michael H Antoni; Jennifer M Knight; Rachel Telles; Susan K Lutgendorf Journal: Integr Cancer Ther Date: 2022 Jan-Dec Impact factor: 3.077
Authors: Lanshan Huang; Melissa J LaBonte; Stephanie G Craig; Stephen P Finn; Emma H Allott Journal: Cancers (Basel) Date: 2022-03-08 Impact factor: 6.639